Methotrexate

甲氨蝶呤

Report date: 2026/05/06 20:02:28
NME

Base Information

Drug NameMethotrexate
Drug Alias NameBrimexate氨甲蝶呤MTX-ATMPs氨甲基叶酸Me totrexat +[41] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDihydrofolate reductase inhibitors
TargetsDihydrofolate reductase
Therapy Area/IndicationsMetastatic breast cancerImmunologic Deficiency SyndromesPsoriasis +[42] 
Global Approved IndicationsPsoriasisArthritis, RheumatoidArthritis, Juvenile +[17] 
Approved Indications in ChinaPsoriasisUterine Cervical NeoplasmsLung Neoplasms +[10] 
Original Approved Country/TerritoryN/A
Original Approved Date1953/01/01
Country/TerritoryCzechiaBelgiumBulgaria +[37] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAntares Pharma
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu shengdi Medicine Co LtdAntares PharmaCincinnati Eye Institute, Southwest Ohio +[23] 
Inactive CompaniesShenzhen Kangzhe Biotechnology Co LtdGlaxosmithkline PlcShahid Beheshti University Of Medical Sciences +[16] 
Active IndicationsMetastatic breast cancerPsoriasisDermatitis, Atopic +[36] 
Inactive IndicationsImmunologic Deficiency SyndromesPregnancy, EctopicEye Diseases +[6] 

Other Information

ATC CodeL01BA01L04AX03
Related LinksWikipediaDrugBankKEGG